Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 124
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Nat Commun ; 10(1): 83, 2019 01 08.
Artículo en Inglés | MEDLINE | ID: mdl-30622257

RESUMEN

Mitochondrial topoisomerase IB (TOP1MT) is a nuclear-encoded topoisomerase, exclusively localized to mitochondria, which resolves topological stress generated during mtDNA replication and transcription. Here, we report that TOP1MT is overexpressed in cancer tissues and demonstrate that TOP1MT deficiency attenuates tumor growth in human and mouse models of colon and liver cancer. Due to their mitochondrial dysfunction, TOP1MT-KO cells become addicted to glycolysis, which limits synthetic building blocks and energy supply required for the proliferation of cancer cells in a nutrient-deprived tumor microenvironment. Mechanistically, we show that TOP1MT associates with mitoribosomal subunits, ensuring optimal mitochondrial translation and assembly of oxidative phosphorylation complexes that are critical for sustaining tumor growth. The TOP1MT genomic signature profile, based on Top1mt-KO liver cancers, is correlated with enhanced survival of hepatocellular carcinoma patients. Our results highlight the importance of TOP1MT for tumor development, providing a potential rationale to develop TOP1MT-targeted drugs as anticancer therapies.


Asunto(s)
Carcinogénesis/patología , Carcinoma Hepatocelular/patología , ADN-Topoisomerasas de Tipo I/metabolismo , Neoplasias Hepáticas Experimentales/patología , Neoplasias Hepáticas/patología , Mitocondrias/metabolismo , Biosíntesis de Proteínas , Animales , Carcinógenos/toxicidad , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/mortalidad , Núcleo Celular/metabolismo , Proliferación Celular , ADN-Topoisomerasas de Tipo I/genética , ADN Mitocondrial/genética , ADN Mitocondrial/aislamiento & purificación , Conjuntos de Datos como Asunto , Metabolismo Energético , Femenino , Fibroblastos , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Glucólisis , Células HCT116 , Humanos , Hígado/citología , Hígado/metabolismo , Hígado/patología , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas Experimentales/inducido químicamente , Neoplasias Hepáticas Experimentales/genética , Neoplasias Hepáticas Experimentales/metabolismo , Masculino , Ratones , Ratones Noqueados , Ratones Desnudos , Mitocondrias/patología , Pronóstico , Análisis de Supervivencia , Ensayos Antitumor por Modelo de Xenoinjerto
2.
Curr Mol Med ; 12(9): 1125-41, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22804236

RESUMEN

In 1994 the first heat shock protein 90 (Hsp90) inhibitor was identified and Hsp90 was reported to be a target for anticancer therapeutics. In the past 18 years there have been 17 distinct Hsp90 inhibitors entered into clinical trial, and the small molecule Hsp90 inhibitors have been highly valuable as probes of the role of Hsp90 and its client proteins in cancer. Although no Hsp90 inhibitor has achieved regulatory approval, recently there has been significant progress in Hsp90 inhibitor clinical development, and in the past year RECIST responses have been documented in HER2-positive breast cancer and EML4-ALK-positive non-small cell lung cancer. All of the clinical Hsp90 inhibitors studied to date are specific in their target, i.e. they bind exclusively to Hsp90 and two related heat shock proteins. However, Hsp90 inhibitors are markedly pleiotropic, causing degradation of over 200 client proteins and impacting critical multiprotein complexes. Furthermore, it has only recently been appreciated that Hsp90 inhibitors can, paradoxically, cause transient activation of the protein kinase clients they are chaperoning, resulting in initiation of signal transduction and significant physiological events in both tumor and tumor microenvironment. An additional area of recent progress in Hsp90 research is in studies of the posttranslational modifications of Hsp90 itself and Hsp90 co-chaperone proteins. Together, a picture is emerging in which the impact of Hsp90 inhibitors is shaped by the tumor intracellular and extracellular milieu, and in which Hsp90 inhibitors impact tumor and host on a microenvironmental and systems level. Here we review the tumor intrinsic and extrinsic factors that impact the efficacy of small molecules engaging the Hsp90 chaperone machine.


Asunto(s)
Antineoplásicos/uso terapéutico , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Neoplasias/tratamiento farmacológico , Animales , Antineoplásicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/patología , Femenino , Proteínas HSP90 de Choque Térmico/metabolismo , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Neoplasias/metabolismo , Neoplasias/patología , Proteínas de Fusión Oncogénica/metabolismo , Receptor ErbB-2/metabolismo
3.
Leukemia ; 15(10): 1537-43, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11587211

RESUMEN

The Bcr-Abl fusion protein drives leukemogenesis and can render leukemia cells resistant to conventional chemotherapy. Geldanamycin (GA), a drug which destabilizes Hsp90-associated proteins, depletes cells of Bcr-Abl, an Hsp90 client, but not of Abl. Both HL60 cells transfected with Bcr-Abl and naturally Ph1-positive K562 leukemia cells are resistant to most cytotoxic drugs, but were found to be sensitive to GA. Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin (DOX) and paclitaxel (PTX). In contrast, in parental HL60 cells, 90 nM GA inhibited PARP cleavage, nuclear fragmentation, and cell death caused by 500 ng/ml DOX. Like GA, STI 571 (an inhibitor of the Abl kinase) sensitized Bcr-Abl-expressing cells to DOX. Unlike GA, STI 571 did not antagonize the cytotoxic effects of DOX in parental HL60 cells. These results indicate that sensitization of Bcr-Abl-expressing cells, but not desensitization of HL60 cells, depends on inhibition of Bcr-Abl. Thus, GA differentially affects leukemia cells depending on their Bcr-Abl expression and selectively increases apoptosis in Bcr-Abl-expressing cells.


Asunto(s)
Proteínas de Fusión bcr-abl/efectos de los fármacos , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Leucemia/patología , Quinonas/farmacología , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Benzoquinonas , Doxorrubicina/farmacología , Interacciones Farmacológicas , Resistencia a Medicamentos , Proteínas de Fusión bcr-abl/biosíntesis , Humanos , Lactamas Macrocíclicas , Leucemia/metabolismo , Paclitaxel/farmacología , Transfección , Células Tumorales Cultivadas/efectos de los fármacos
4.
Cancer Res ; 61(4): 1671-7, 2001 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-11245482

RESUMEN

Beta-catenin undergoes both serine and tyrosine phosphorylation. Serine phosphorylation in the amino terminus targets beta-catenin for proteasome degradation, whereas tyrosine phosphorylation in the COOH terminus influences interaction with E-cadherin. We examined the tyrosine phosphorylation status of beta-catenin in melanoma cells expressing proteasome-resistant beta-catenin, as well as the effects that perturbation of beta-catenin tyrosine phosphorylation had on its association with E-cadherin and on its transcriptional activity. Beta-catenin is tyrosine phosphorylated in three melanoma cell lines and associates with both the ErbB2 receptor tyrosine kinase and the LAR receptor tyrosine phosphatase. Geldanamycin, a drug which destabilizes ErbB2, caused rapid cellular depletion of the kinase and loss of its association with beta-catenin without perturbing either LAR or beta-catenin levels or LAR/beta-catenin association. Geldanamycin also stimulated tyrosine dephosphorylation of beta-catenin and increased beta-catenin/E-cadherin association, resulting in substantially decreased cell motility. Geldanamycin also decreased the nuclear beta-catenin level and inhibited beta-catenin-driven transcription, as assessed using two different beta-catenin-sensitive reporters and the endogenous cyclin D1 gene. These findings were confirmed by transient transfection of two beta-catenin point mutants, Tyr-654Phe and Tyr-654Glu, which, respectively, mimic the dephosphorylated and phosphorylated states of Tyr-654, a tyrosine residue contained within the beta-catenin-ErbB2-binding domain. These data demonstrate that the functional activity of proteasome-resistant beta-catenin is regulated further by geldanamycin-sensitive tyrosine phosphorylation in melanoma cells.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Cadherinas/metabolismo , Cisteína Endopeptidasas/metabolismo , Proteínas del Citoesqueleto/metabolismo , Melanoma/metabolismo , Complejos Multienzimáticos/metabolismo , Proteínas del Tejido Nervioso , Quinonas/farmacología , Receptor ErbB-2/metabolismo , Transactivadores , Benzoquinonas , Movimiento Celular/efectos de los fármacos , Cisteína Endopeptidasas/efectos de los fármacos , Inhibidores de Cisteína Proteinasa/farmacología , Proteínas del Citoesqueleto/genética , Humanos , Lactamas Macrocíclicas , Melanoma/tratamiento farmacológico , Melanoma/genética , Melanoma/patología , Complejos Multienzimáticos/efectos de los fármacos , Fosforilación , Mutación Puntual , Complejo de la Endopetidasa Proteasomal , Proteínas Tirosina Fosfatasas/metabolismo , Proteínas Tirosina Fosfatasas Clase 2 Similares a Receptores , Proteínas Tirosina Fosfatasas Clase 4 Similares a Receptores , Receptores de Superficie Celular/metabolismo , Transcripción Genética/efectos de los fármacos , Activación Transcripcional , Transfección , Células Tumorales Cultivadas , Tirosina/metabolismo , beta Catenina
5.
J Biol Chem ; 276(21): 18497-506, 2001 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-11279110

RESUMEN

The wild type p53 tumor suppressor protein is rapidly degraded in normal cells by MDM2, the ubiquitin ligase that serves as the key regulator of p53 function by modulating protein stability. Cellular exposure to genotoxic stress triggers the stabilization of p53 by multiple pathways that converge upon interference with MDM2 function. In this study, we first investigated the ability of HDM2 (MDM2 human homologue) to degrade endogenous p53 in neuroblastoma (NB). Although the p53 protein in NB has been reported to be constitutively stabilized, we find that HDM2 in NB is functional and facilitates the rapid turnover of p53 in nonstressed cells via the proteasome pathway. Second, we examined the relationship between p53 and HDM2 in the adriamycin-mediated stabilization of p53 in NB. We demonstrate that while p53 stabilization depends neither upon the phosphorylation of specific N-terminal sites nor upon dissociation from HDM2, it requires inactivation of functional HDM2. In support of this notion, p53 stabilization following adriamycin resulted in an inhibition of both p53 ubiquitination and HDM2 ligase activity. Taken together, these data implicate a requirement for enzymatic inactivation of HDM2 as a novel mechanism for p53 stabilization in the DNA damage response pathway.


Asunto(s)
Neuroblastoma/metabolismo , Proteínas Nucleares , Proteínas Proto-Oncogénicas/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Doxorrubicina/farmacología , Doxorrubicina/uso terapéutico , Humanos , Proteínas de Neoplasias/metabolismo , Neuroblastoma/tratamiento farmacológico , Proteínas Proto-Oncogénicas c-mdm2 , Células Tumorales Cultivadas
6.
Cancer Chemother Pharmacol ; 48(6): 435-45, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11800023

RESUMEN

PURPOSE: Radicicol is a novel hsp90 antagonist, distinct from the chemically unrelated benzoquinone ansamycin compounds, geldanamycin and herbimycin. Both geldanamycin and radicicol bind in the aminoterminal nucleotide-binding pocket of hsp90, destabilizing the hsp90 client proteins, many of which are essential for tumor cell growth. We describe here antitumor activity of a novel oxime derivative of radicicol, KF58333. We also investigated the mechanism of antitumor activity of KF58333 in comparison with its oxime isomer KF58332. METHODS: Antiproliferative activities were determined in a panel of breast cancer cell lines in vitro. We also examined inhibition of hsp90 function and apoptosis induction in erbB2-overexpressing human breast carcinoma KPL-4 cells in vitro. Direct binding activity to hsp90 was assessed by hsp90-binding assays using geldanamycin or radicicol beads. In animal studies, we investigated plasma concentrations of these compounds after i.v. injection in BALB/c mice and antitumor activity against KPL-4 cells transplanted into nude mice. Inhibition of hsp90 function and induction of apoptosis in vivo were investigated using tumor specimens from drug-treated animals. RESULTS: KF58333 showed potent antiproliferative activity against all breast cancer cell lines tested in vitro, and was more potent than its stereoisomer KF58332. These results are consistent with the ability of KF58333 to deplete hsp90 client proteins and the induction of apoptosis in KPL-4 cells in vitro. Interestingly, KF58333, but not KF58332, showed significant in vivo antitumor activity accompanied by induction of apoptosis in KPL-4 human breast cancer xenografts. Although the plasma concentrations of these compounds were equivalent, KF58333, but not KF58332, depleted hsp90 client proteins such as erbB2, raf-1 and Akt in the tumor specimen recovered from nude mice. CONCLUSIONS: These results suggest that inhibition of hsp90 function, which causes depletion of hsp90 client proteins in tumor, contributes to the antitumor activity of KF58333, and that the stereochemistry of the oxime moiety is important for the biological activity of radicicol oxime derivatives.


Asunto(s)
Apoptosis/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Proteínas HSP90 de Choque Térmico/metabolismo , Lactonas/farmacología , Animales , Neoplasias de la Mama/patología , Femenino , Regulación de la Expresión Génica , Genes erbB-2 , Humanos , Inyecciones Intravenosas , Macrólidos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Oximas/farmacología , Estereoisomerismo , Relación Estructura-Actividad , Células Tumorales Cultivadas
7.
Blood ; 96(6): 2284-91, 2000 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-10979978

RESUMEN

Chronic myelogenous leukemia (CML) is a clonal disorder of a pluripotent hematopoietic stem cells characterized by a chimeric bcr-abl gene giving rise to a p210(Bcr-Abl) protein with dysregulated tyrosine kinase activity. Radicicol, a macrocyclic antifungal antibiotic, binds to the N-terminal of heat shock protein 90 (Hsp90) and destabilizes Hsp90-associated proteins such as Raf-1. This study investigated the effect of radicicol, novel oxime derivatives of radicicol (KF25706 and KF58333), and herbimycin A (HA), a benzoquinoid ansamycin antibiotic, on the growth and differentiation of human K562 CML cells. Although KF25706 and KF58333 induced the expression of glycophorin A in K562 cells, radicicol and HA caused erythroid differentiation transiently. Cell cycle analysis showed that G(1) phase accumulation was observed in K562 cells treated with KF58333. KF58333 treatment depleted p210(Bcr-Abl), Raf-1, and cellular tyrosine phosphorylated proteins in K562 cells, whereas radicicol and HA showed transient depletion of these proteins. KF58333 also down-regulated the level of cell cycle-dependent kinases 4 and 6 and up-regulated cell cycle-dependent kinase inhibitor p27(Kip1) protein without an effect on the level of Erk and Hsp90 proteins. Immunoprecipitation analysis showed that p210(Bcr-Abl) formed multiple complexes with Hsp90, some containing p23 and others Hsp70; KF58333 treatment dissociated p210(Bcr-Abl) from Hsp90/p23 chaperone complexes. Furthermore, KF58333 induced apoptosis in K562 cells and administration of KF58333 prolonged the survival time of SCID mice inoculated with K562 cells. These results suggest that KF58333 may have therapeutic potential for the treatment of CML that involves abnormal cellular proliferation induced by p210(Bcr-Abl).


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Antifúngicos/farmacología , Proteínas de Fusión bcr-abl/metabolismo , Fase G1/efectos de los fármacos , Proteínas HSP90 de Choque Térmico/metabolismo , Lactonas/farmacología , Leucemia Mielógena Crónica BCR-ABL Positiva , Quinonas/farmacología , Animales , Antibióticos Antineoplásicos/química , Antibióticos Antineoplásicos/uso terapéutico , Antifúngicos/química , Antifúngicos/uso terapéutico , Benzoquinonas , Diferenciación Celular/efectos de los fármacos , Eritroblastos/efectos de los fármacos , Eritroblastos/patología , Humanos , Células K562 , Lactamas Macrocíclicas , Lactonas/química , Lactonas/uso terapéutico , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Leucemia Mielógena Crónica BCR-ABL Positiva/metabolismo , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Macrólidos , Ratones , Quinonas/química , Quinonas/uso terapéutico , Rifabutina/análogos & derivados
8.
Cell Growth Differ ; 11(7): 355-60, 2000 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10939589

RESUMEN

Several important signaling proteins including transcription factors and protein kinases depend on heat shock protein (Hsp)-90 for stability. p210bcr-abl, a protein expressed in chronic myelogenous leukemia, is functionally inhibited by the benzoquinone ansamycin herbimycin A. Benzoquinone ansamycins also bind to and inhibit the activity of Hsp90. We now demonstrate that p210bcr-abl is complexed with Hsp90 and its cochaperone p23 in K562 chronic myelogenous leukemia cells. Brief exposure to the benzoquinone ansamycin Hsp90 inhibitor geldanamycin (GA) decreases the association of p210bcr-abl with Hsp90 and p23 and increases its association with the chaperones Hsp70 and p60Hop. GA has a similar effect on chaperone association with v-src, another Hsp90-dependent oncogenic kinase. Loss of Hsp90/p23 association and acquisition of Hsp70/p60Hop association of both p210bcr-abl and v-src precede GA-induced degradation of these kinases. GA-induced degradation is mediated by the proteasome because proteasome inhibitors block the effects of GA, causing both p210bcr-abl and v-src to accumulate in a detergent-insoluble cellular fraction. Both p210bcr-abl and v-src are more susceptible to GA-induced degradation than are their normal cellular counterparts, c-abl and c-src.


Asunto(s)
Cisteína Endopeptidasas/metabolismo , Inhibidores Enzimáticos/farmacología , Proteínas de Fusión bcr-abl/metabolismo , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Chaperonas Moleculares/metabolismo , Complejos Multienzimáticos/metabolismo , Proteína Oncogénica pp60(v-src)/metabolismo , Quinonas/farmacología , Células 3T3 , Animales , Benzoquinonas , Extractos Celulares , Línea Celular , Células HL-60 , Proteínas HSP90 de Choque Térmico/metabolismo , Humanos , Immunoblotting , Oxidorreductasas Intramoleculares , Células K562 , Lactamas Macrocíclicas , Sustancias Macromoleculares , Ratones , Fosfoproteínas/metabolismo , Pruebas de Precipitina , Prostaglandina-E Sintasas , Complejo de la Endopetidasa Proteasomal , Conformación Proteica , Proteínas Proto-Oncogénicas c-abl/antagonistas & inhibidores , Proteínas Proto-Oncogénicas c-abl/metabolismo , Proteínas Proto-Oncogénicas pp60(c-src)/antagonistas & inhibidores , Proteínas Proto-Oncogénicas pp60(c-src)/metabolismo , Receptores de Progesterona/metabolismo , Familia-src Quinasas/metabolismo
9.
J Biol Chem ; 275(47): 37181-6, 2000 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-10945979

RESUMEN

Heat shock protein 90 (Hsp90), one of the most abundant chaperones in eukaryotes, participates in folding and stabilization of signal-transducing molecules including steroid hormone receptors and protein kinases. The amino terminus of Hsp90 contains a non-conventional nucleotide-binding site, related to the ATP-binding motif of bacterial DNA gyrase. The anti-tumor agents geldanamycin and radicicol bind specifically at this site and induce destabilization of Hsp90-dependent client proteins. We recently demonstrated that the gyrase inhibitor novobiocin also interacts with Hsp90, altering the affinity of the chaperone for geldanamycin and radicicol and causing in vitro and in vivo depletion of key regulatory Hsp90-dependent kinases including v-Src, Raf-1, and p185(ErbB2). In the present study we used deletion/mutation analysis to identify the site of interaction of novobiocin with Hsp90, and we demonstrate that the novobiocin-binding site resides in the carboxyl terminus of the chaperone. Surprisingly, this motif also recognizes ATP, and ATP and novobiocin efficiently compete with each other for binding to this region of Hsp90. Novobiocin interferes with association of the co-chaperones Hsc70 and p23 with Hsp90. These results identify a second site on Hsp90 where the binding of small molecule inhibitors can significantly impact the function of this chaperone, and they support the hypothesis that both amino- and carboxyl-terminal domains of Hsp90 interact to modulate chaperone activity.


Asunto(s)
Adenosina Trifosfato/metabolismo , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Novobiocina/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Pollos , Inhibidores Enzimáticos/metabolismo , Proteínas HSP90 de Choque Térmico/genética , Proteínas HSP90 de Choque Térmico/metabolismo , Lactonas/metabolismo , Macrólidos , Datos de Secuencia Molecular , Mutación Puntual , Unión Proteica , Conformación Proteica , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Conejos , Relación Estructura-Actividad
10.
Oncogene ; 18(47): 6460-8, 1999 Nov 11.
Artículo en Inglés | MEDLINE | ID: mdl-10597248

RESUMEN

BRCA1, a tumor suppressor protein implicated in hereditary forms of breast and ovarian cancer, is transcriptionally regulated in a proliferation-dependent manner. In this study, we demonstrate a substantial role for proteolysis in regulating the BRCA1 steady-state protein level in several cell lines. N-acetyl-leu-leu-norleucinal (ALLN), an inhibitor of the proteasome, calpain, and cathepsins, caused BRCA1 protein to accumulate in the nucleus of several human breast, prostate, and melanoma cell lines which express low or undetectable basal levels of BRCA1 protein, but not in cells with high basal expression of BRCA1. Protease inhibition did not increase BRCA1 synthesis, nor change its mRNA level, but it dramatically prolonged the protein's half-life. In contrast to ALLN, lactacystin and PS341, two specific proteasome inhibitors, as well as calpastatin peptide and PD150606, two selective calpain inhibitors, had no effect on BRCA1 stability, whereas ALLM, an effective calpain and cathepsin inhibitor but weak proteasome inhibitor, did stimulate accumulation of BRCA1. Moreover, three inhibitors of acidic cysteine proteases, chloroquine, ammonium chloride and bafilomycin, were as effective as ALLN. These results demonstrate that degradation by a cathepsin-like protease in fine balance with BRCA1 transcription is responsible for maintaining the low steady-state level of BRCA1 protein seen in many cancer cells.


Asunto(s)
Proteína BRCA1/genética , Regulación de la Expresión Génica , Carioferinas , Receptores Citoplasmáticos y Nucleares , Proteína BRCA1/biosíntesis , Proteína BRCA1/metabolismo , Calpaína/metabolismo , Proteínas Portadoras/metabolismo , Núcleo Celular/metabolismo , Cisteína Endopeptidasas/metabolismo , Dactinomicina/antagonistas & inhibidores , Regulación hacia Abajo/efectos de los fármacos , Endopeptidasas/metabolismo , Semivida , Humanos , Hidrólisis , Leupeptinas/farmacología , Complejos Multienzimáticos/metabolismo , Complejo de la Endopetidasa Proteasomal , ARN Mensajero/genética , ARN Mensajero/metabolismo , Células Tumorales Cultivadas , Proteína Exportina 1
11.
Mol Endocrinol ; 13(9): 1435-48, 1999 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10478836

RESUMEN

The Hsp90 family of proteins in mammalian cells consists of Hsp90 alpha and beta, Grp94, and Trap-1 (Hsp75). Radicicol, an antifungal antibiotic that inhibits various signal transduction proteins such as v-src, ras, Raf-1, and mos, was found to bind to Hsp90, thus making it the prototype of a second class of Hsp90 inhibitors, distinct from the chemically unrelated benzoquinone ansamycins. We have used two novel methods to immobilize radicicol, allowing for detailed analyses of drug-protein interactions. Using these two approaches, we have studied binding of the drug to N-terminal Hsp90 point mutants expressed by in vitro translation. The results point to important drug contacts with amino acids inside the N-terminal ATP/ADP-binding pocket region and show subtle differences when compared with geldanamycin binding. Radicicol binds more strongly to Hsp90 than to Grp94, the Hsp90 homolog that resides in the endoplasmic reticulum. In contrast to Hsp90, binding of radicicol to Grp94 requires both the N-terminal ATP/ADP-binding domain as well as the adjacent negatively charged region. Radicicol also specifically binds to yeast Hsp90, Escherichia coli HtpG, and a newly described tumor necrosis factor receptor-interacting protein, Trap-1, with greater homology to bacterial HtpG than to Hsp90. Thus, the radicicol-binding site appears to be specific to and is conserved in all members of the Hsp90 family of molecular chaperones from bacteria to mammals, but is not present in other molecular chaperones with nucleotide-binding domains.


Asunto(s)
Proteínas HSP90 de Choque Térmico/metabolismo , Lactonas/metabolismo , Chaperonas Moleculares/metabolismo , Células 3T3 , Animales , Proteínas Bacterianas/metabolismo , Benzoquinonas , Sitios de Unión/genética , Unión Competitiva , Biotinilación , Línea Celular Transformada , Cromatografía de Afinidad , Proteínas de Unión al ADN/metabolismo , Proteínas Fúngicas/metabolismo , Proteínas HSP70 de Choque Térmico/metabolismo , Proteínas HSP90 de Choque Térmico/química , Humanos , Lactamas Macrocíclicas , Lactonas/química , Macrólidos , Proteínas de la Membrana/metabolismo , Ratones , Mutación , Unión Proteica , Quinonas/metabolismo , Células Tumorales Cultivadas
12.
Cancer Res ; 59(12): 2931-8, 1999 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-10383157

RESUMEN

Radicicol, a macrocyclic antifungal antibiotic, has been shown to bind to the heat shock protein 90 (Hsp90) chaperone, interfering with its function. Hsp90 family chaperones have been shown to associate with several signaling molecules and play an essential role in signal transduction, which is important for tumor cell growth. Because radicicol lacks antitumor activity in vivo in experimental animal models, we examined the antitumor activity of a novel radicicol oxime derivative, radicicol 6-oxime (KF25706), on human tumor cell growth both in vitro and in vivo. KF25706 showed potent antiproliferative activities against various human tumor cell lines in vitro and inhibited v-src- and K-ras-activated signaling as well as radicicol. In addition, Hsp90 family chaperone-associated proteins, such as p185erbB2, Raf-1, cyclin-dependent kinase 4, and mutant p53, were depleted by KF25706 at a dose comparable to that required for antiproliferative activity. KF25706 was also shown to compete with geldanamycin for binding to Hsp90. KF29163, which is an inactive derivative of radicicol, was less potent both in p185erbB2 depletion and Hsp90 binding. More importantly, KF25706 showed significant growth-inhibitory activity against human breast carcinoma MX-1 cells transplanted into nude mice at a dose of 100 mg/kg twice daily for five consecutive i.v. injections. KF25706 was also shown to possess antitumor activity against human breast carcinoma MCF-7, colon carcinoma DLD-1, and vulval carcinoma A431 cell lines in vivo in an animal model. Finally, we confirmed the depletion of Hsp90-associated signaling molecules (Raf-1 and cyclin-dependent kinase 4) with ex vivo Western blotting analysis using MX-1 xenografts. In agreement with in vivo antitumor activity, KF25706 depleted Hsp90-associated molecules in vivo, whereas KF29163 and radicicol did not show this activity in vivo. Taken together, these results suggest that antitumor activity of KF25706 may be mediated, at least in part, by binding to Hsp90 family proteins and destabilization of Hsp90-associated signaling molecules.


Asunto(s)
Antibióticos Antineoplásicos/farmacología , Proteínas HSP90 de Choque Térmico/metabolismo , Lactonas/química , Lactonas/farmacología , Animales , Antibióticos Antineoplásicos/química , Antibióticos Antineoplásicos/metabolismo , Benzoquinonas , Línea Celular , Ensayos de Selección de Medicamentos Antitumorales , Genes ras , Proteínas HSP90 de Choque Térmico/antagonistas & inhibidores , Humanos , Lactamas Macrocíclicas , Lactonas/metabolismo , Macrólidos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Proteína Oncogénica pp60(v-src)/metabolismo , Quinonas/farmacología , Transducción de Señal/efectos de los fármacos , Células Tumorales Cultivadas
14.
Cancer Chemother Pharmacol ; 42(4): 273-9, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9744771

RESUMEN

PURPOSE: Benzoquinone ansamycins are antibiotics with anticancer potential. First described as tyrosine kinase inhibitors, they are now frequently used to target HSP90 chaperone function. While herbimycin A and geldanamycin (GA) have been widely used in preclinical studies, both drugs are poor candidates for clinical trials owing to their in vivo toxicity and lack of stability. We therefore examined the biologic effects of 17-allylamino-17-demethoxygeldanamycin (17-AG), an ansamycin derivative with lower in vivo toxicity than GA. METHODS: Binding of 17-AG to HSP90 was studied in vitro using a GA-affinity beads competition assay. We analyzed the drug-induced destabilization of p185erbB2, Raf-1 and mutant p53 in SKBR3 breast cancer cells by Western blotting. The antiproliferative activities of 17-AG and GA were compared using the MTT assay. RESULTS: We found that, in a similar manner to GA itself, 17-AG bound specifically to HSP90. It also led to degradation of the receptor tyrosine kinase p185erbB2, the serine/threonine kinase Raf-1 and mutant p53. Both GA and 17-AG displayed comparable antiproliferative effects in SKBR3 and MCF7 cells. Even though HSP90 binding by 17-AG was weaker than by GA, 17-AG and GA caused biologic effects in tumor cells at similar doses. CONCLUSION: 17-AG shares the important biologic features of its parent compound GA. Since 17-AG has a better toxicity profile than GA, it is an interesting candidate benzoquinone ansamycin for clinical development.


Asunto(s)
Antibióticos Antineoplásicos/metabolismo , Inhibidores Enzimáticos/metabolismo , Proteínas HSP90 de Choque Térmico/metabolismo , Quinonas/metabolismo , Rifabutina/análogos & derivados , Células 3T3 , Animales , Antibióticos Antineoplásicos/farmacología , Benzoquinonas , División Celular/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Lactamas Macrocíclicas , Ratones , Mutación/efectos de los fármacos , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/genética , Proteínas Proto-Oncogénicas c-raf/química , Proteínas Proto-Oncogénicas c-raf/metabolismo , Quinonas/farmacología , Receptor ErbB-2/química , Receptor ErbB-2/metabolismo , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/química , Proteína p53 Supresora de Tumor/metabolismo
15.
Cell Stress Chaperones ; 3(2): 100-8, 1998 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-9672245

RESUMEN

The molecular chaperone Hsp90 plays an essential role in the folding and function of important cellular proteins including steroid hormone receptors, protein kinases and proteins controlling the cell cycle and apoptosis. A 15 A deep pocket region in the N-terminal domain of Hsp90 serves as an ATP/ADP-binding site and has also been shown to bind geldanamycin, the only specific inhibitor of Hsp90 function described to date. We now show that radicicol, a macrocyclic antifungal structurally unrelated to geldanamycin, also specifically binds to Hsp90. Moreover, radicicol competes with geldanamycin for binding to the N-terminal domain of the chaperone, expressed either by in vitro translation or as a purified protein, suggesting that radicicol shares the geldanamycin binding site. Radicicol, as does geldanamycin, also inhibits the binding of the accessory protein p23 to Hsp90, and interferes with assembly of the mature progesterone receptor complex. Radicicol does not deplete cells of Hsp90, but rather increases synthesis as well as the steady-state level of this protein, similar to a stress response. Finally, radicicol depletes SKBR3 cells of p185erbB2, Raf-1 and mutant p53, similar to geldanamycin. Radicicol thus represents a structurally unique antibiotic, and the first non-benzoquinone ansamycin, capable of binding to Hsp90 and interfering with its function.


Asunto(s)
Antibióticos Antineoplásicos/farmacocinética , Antifúngicos/farmacocinética , Proteínas HSP90 de Choque Térmico/química , Proteínas HSP90 de Choque Térmico/metabolismo , Lactonas/farmacología , Lactonas/farmacocinética , Quinonas/farmacocinética , Animales , Benzoquinonas , Sitios de Unión , Unión Competitiva , Neoplasias de la Mama , División Celular/efectos de los fármacos , Pollos , Cromatografía de Afinidad , Femenino , Humanos , Lactamas Macrocíclicas , Macrólidos , Estructura Molecular , Quinonas/farmacología , Células Tumorales Cultivadas
18.
Oncogene ; 16(9): 1131-9, 1998 Mar 05.
Artículo en Inglés | MEDLINE | ID: mdl-9528855

RESUMEN

N-myc is a short-lived transcription factor, frequently amplified in human neuroblastomas. The ubiquitin-proteasome system is involved in the degradation of many short-lived cellular proteins and previous studies have shown that ubiquitin-dependent proteolysis is implicated in the turn-over of N-myc in vitro. However, calpain has also been implicated in N-myc degradation in vitro. Here we report that, in vivo, N-myc is a sensitive substrate for the 26S proteasome in N-myc amplified neuroblastoma cells. We observed that inhibition of the 26S proteasome with two inhibitors, ALLnL and lactacystin, led to an elevation of the N-myc protein steady-state and increased N-myc protein polyubiquitination, as revealed by ubiquitin Western blotting. Pulse-chase experiments have shown that the increased N-myc levels resulted from stabilization of the protein. In contrast treatment with several calpain and cathepsin inhibitors failed to block N-myc degradation in vivo. Furthermore, fluorescence microscopy of ALLnL-treated cells localized N-myc exclusively to the nuclear compartment, suggesting the absence of a requirement for transport to the cytoplasm prior to degradation.


Asunto(s)
Inhibidores de Cisteína Proteinasa/farmacología , Péptido Hidrolasas/metabolismo , Complejo de la Endopetidasa Proteasomal , Proteínas Proto-Oncogénicas c-myc/metabolismo , Acetilcisteína/análogos & derivados , Acetilcisteína/farmacología , Calpaína/metabolismo , Humanos , Lisosomas/enzimología , Neuroblastoma , Especificidad por Sustrato , Células Tumorales Cultivadas , Ubiquitinas/metabolismo
19.
Nature ; 392(6674): 405-8, 1998 Mar 26.
Artículo en Inglés | MEDLINE | ID: mdl-9537326

RESUMEN

Although hypoxia (lack of oxygen in body tissues) is perhaps the most physiological inducer of the wild-type p53 gene, the mechanism of this induction is unknown. Cells may detect low oxygen levels through a haem-containing sensor protein. The hypoxic state can be mimicked by using cobalt chloride and the iron chelator desferrioxamine: like hypoxia, cobalt chloride and desferrioxamine activate hypoxia-inducible factor 1alpha (HIF-1alpha), which stimulates the transcription of several genes that are associated with hypoxia. Here we show that these treatments induce accumulation of wild-type p53 through HIF-1alpha-dependent stabilization of p53 protein. Induction of p53 does not occur in either a mutant hepatoma cell line that is unable to induce HIF-1alpha or embryonic stem cells derived from mice lacking HIF-1beta. HIF-1alpha is found in p53 immunoprecipitates from MCF7 cells that express wild-type p53 and are either hypoxic or have been exposed to desferrioxamine. Similarly, anti-haemagglutinin immunoprecipitates from lysates of normoxic PC3M cells that had been co-transfected with haemagglutinin-tagged HIF-1alpha and wild-type p53 also contain p53. Transfection of normoxic MCF7 cells with HIF-1alpha stimulates a co-transfected p53-dependent reporter plasmid and increases the amount of endogenous p53. Our results suggest that hypoxic induction of transcriptionally active wild-type p53 is achieved as a result of the stabilization of p53 by its association with HIF-1alpha.


Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas Nucleares/metabolismo , Factores de Transcripción , Proteína p53 Supresora de Tumor/metabolismo , Animales , Hipoxia de la Célula , Cobalto/farmacología , Proteínas de Unión al ADN/genética , Deferoxamina/farmacología , Factor 1 Inducible por Hipoxia , Subunidad alfa del Factor 1 Inducible por Hipoxia , Ratones , Mutación , Proteínas Nucleares/genética , Transcripción Genética , Transfección , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/efectos de los fármacos , Proteína p53 Supresora de Tumor/genética
20.
Biochem Biophys Res Commun ; 239(3): 655-9, 1997 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-9367823

RESUMEN

The Raf-1-MEK-MAPK pathway plays an important role in transducing extracellular growth factor signaling into altered nuclear transcription factor function. The benzoquinone ansamycin Geldanamycin (GA) specifically binds to the heat shock protein HSP90 and alters its complex with Raf-1. This leads to a decrease in Raf-1 levels and to disruption of the Raf-1-MEK-MAPK signaling pathway. The enhanced degradation of Raf-1 protein was prevented by inhibitors of the proteasome, while inhibition of lysosomal or other proteases was ineffective. Raf-1 that was protected from GA-induced degradation was of higher molecular weight and showed a laddering pattern consistent with its polyubiquitination. Unlike Raf-1 in untreated cells, the protein was insoluble in Triton X100- or NP40-based buffers. Signaling through this pathway was inhibited by GA, concomitant with loss of Raf-1 protein, but was restored if Raf-1 was protected from GA-induced degradation by proteasome inhibitors.


Asunto(s)
Cisteína Endopeptidasas/metabolismo , Cisteína Endopeptidasas/fisiología , Complejos Multienzimáticos/metabolismo , Complejos Multienzimáticos/fisiología , Proteínas Proto-Oncogénicas c-raf/metabolismo , Quinonas/farmacología , Células 3T3 , Animales , Benzoquinonas , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Estabilidad de Enzimas/efectos de los fármacos , Lactamas Macrocíclicas , Ratones , Complejo de la Endopetidasa Proteasomal , Proteínas Proto-Oncogénicas c-raf/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA